Trial Profile
A Phase Ib Study of Pembrolizumab (MK-3475) in Chinese Subjects With Locally Advanced or Metastatic Melanoma (Keynote-151)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Dec 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms Keynote-151; MK-3475-151/KEYNOTE-151
- Sponsors Merck Sharp & Dohme Corp.
- 24 Oct 2023 Results of more than 5 y of follow-up were presented at the 48th European Society for Medical Oncology Congress.
- 06 Dec 2022 Status changed from active, no longer recruiting to completed.
- 29 Jul 2022 Planned End Date changed from 31 Jul 2022 to 30 Nov 2022.